ROCKWELL MEDICAL, INC.
RMTINasdaq
$6.13
↑ +6.9%Jul 17 close · end-of-day
Price
1Y↓ -42.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$241.4M
Enterprise Value
$240.7M
P/E
—
P/S
3.6
P/B
6.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$67.7M
Net Income (TTM)
-$5.4M
Free Cash Flow (TTM)
—
Gross Margin
17.1%
Operating Margin
-7.1%
Net Margin
-8.0%
ROE
-15.1%
ROIC
-10.8%
Debt / Equity
0.2
Net Cash
$695,000.00
Return 1Y
-43.8%
Company profile
Rockwell Medical, Inc. targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream.
- CEO
- Mark Strobeck
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 300
- Headquarters
- Michigan
- Website
- rockwellmed.com
Management & directors
- Chole TimothySVP and CCO
- Hunter HeatherSVP, Chief Operating Officer
- Neri JesseSVP and CFO
- Strobeck MarkPresident and CEO
- Timmins Megan C.EVP, CLO & Secretary
Roles derived from SEC Form 4 filings.
Earnings
RMTI Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.3M↓ -8.3%
Diluted EPS-$0.040.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $62.2M | $61.9M | $72.8M | $83.6M | $101.5M | $69.3M |
| Gross profit | $2.7M | -$2.4M | $4.1M | $8.7M | $17.5M | $11.7M |
| Operating income | -$28.4M | -$30.3M | -$16.8M | -$6.7M | $608,000.00 | -$4.7M |
| Net income | -$30.9M | -$32.7M | -$18.7M | -$8.4M | -$480,000.00 | -$5.3M |
| Diluted EPS | -$0.41 | -$3.83 | -$1.31 | -$0.37 | -$0.03 | -$0.15 |
| Operating cash flow | -$29.6M | -$33.5M | -$16.9M | -$9.4M | $4.2M | -$659,000.00 |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 4.4% | -3.9% | 5.6% | 10.4% | 17.2% | 16.9% |
| Operating margin | -45.7% | -49.0% | -23.0% | -8.0% | 0.6% | -6.8% |
| Net margin | -49.7% | -52.8% | -25.7% | -10.1% | -0.5% | -7.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $25.8M | $28.3M | $24.7M | $18.9M | $16.1M | $15.9M | $18.3M | $17.3M |
| Gross profit | $4.5M | $6.2M | $3.6M | $3.0M | $2.5M | $2.3M | $3.9M | $2.9M |
| Operating income | $515,000.00 | $1.9M | -$519,000.00 | -$1.4M | -$1.3M | -$1.6M | -$398,000.00 | -$1.5M |
| Net income | $343,000.00 | $1.7M | -$756,000.00 | -$1.5M | -$1.5M | -$1.8M | -$554,000.00 | -$1.6M |
| Diluted EPS | $0.01 | $0.04 | -$0.02 | -$0.04 | -$0.05 | -$0.05 | -$0.01 | -$0.04 |
| Operating cash flow | $1.4M | $4.3M | $865,000.00 | -$3.5M | $1.8M | -$1.3M | $2.3M | -$167,000.00 |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 17.6% | 22.0% | 14.7% | 16.1% | 15.6% | 14.3% | 21.1% | 16.7% |
| Operating margin | 2.0% | 6.8% | -2.1% | -7.2% | -8.4% | -9.9% | -2.2% | -8.5% |
| Net margin | 1.3% | 5.9% | -3.1% | -8.0% | -9.3% | -11.0% | -3.0% | -9.3% |
Company news
Jul 20, 2026
Jul 16, 2026
Jul 14, 2026
Jun 29, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Dawson Joseph H | Award | 9,633 | $0.00 | $0.00 | filing |
| 2026-07-01 | Nissenson Allen | Award | 9,633 | $0.00 | $0.00 | filing |
| 2026-07-01 | Lau Joan | Award | 9,633 | $0.00 | $0.00 | filing |
| 2026-07-01 | Radie Robert S | Award | 9,633 | $0.00 | $0.00 | filing |
| 2026-07-01 | COOPER JOHN G | Award | 9,633 | $0.00 | $0.00 | filing |
| 2026-07-01 | Chole Timothy· SVP and CCO | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Hunter Heather· Chief Operating Officer | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | TIMMINS MEGAN C.· EVP, CLO & Secretary | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Neri Jesse· SVP and CFO | Award | 15,000 | $0.00 | $0.00 | filing |
| 2026-07-01 | Strobeck Mark· President and CEO | Award | 30,000 | $0.00 | $0.00 | filing |
| 2026-03-14 | Strobeck Mark· President and CEO | Tax withholding | 7,333 | $0.90 | $6,599.70 | filing |
| 2026-03-14 | TIMMINS MEGAN C.· See Remarks | Tax withholding | 3,667 | $0.90 | $3,300.30 | filing |
| 2026-03-14 | Chole Timothy· SVP and CCO | Tax withholding | 2,444 | $0.90 | $2,199.60 | filing |
| 2026-03-14 | Hunter Heather· Chief Operating Officer | Tax withholding | 2,444 | $0.90 | $2,199.60 | filing |
| 2026-03-14 | Neri Jesse· SVP and CFO | Tax withholding | 2,444 | $0.90 | $2,199.60 | filing |
| 2026-01-02 | Hunter Heather· Chief Operating Officer | Sale | 2,868 | $0.84 | $2,396.21 | filing |
| 2026-01-02 | Neri Jesse· SVP and CFO | Sale | 886 | $0.84 | $740.25 | filing |
| 2025-11-18 | COOPER JOHN G | Sale | 5,079 | $0.87 | $4,418.73 | filing |
| 2025-11-17 | Dawson Joseph H | Award | 25,000 | $0.00 | $0.00 | filing |
| 2025-10-01 | Strobeck Mark· President and CEO | Sale | 6,926 | $1.19 | $8,241.94 | filing |
| 2025-10-01 | Chole Timothy· SVP and CCO | Sale | 2,868 | $1.19 | $3,412.92 | filing |
| 2025-10-01 | Hunter Heather· SVP, Chief Operating Officer | Sale | 2,868 | $1.19 | $3,412.92 | filing |
| 2025-10-01 | Neri Jesse· SVP and CFO | Sale | 886 | $1.19 | $1,054.34 | filing |
| 2025-07-01 | Strobeck Mark· President and CEO | Sale | 6,926 | $0.82 | $5,679.32 | filing |
| 2025-07-01 | Strobeck Mark· President and CEO | Sale | 6,926 | $0.82 | $5,679.32 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.